Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 6/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18277749 | 0.96 | MAPK10 (0.40) | MAPK10MAPK8MAPK9CCNT1CCNA2 | |
| SCHEMBL18277815 | 0.94 | MAPK10 (0.38) | MAPK10MAPK8MAPK9CCNT1CCNA2 | |
| SCHEMBL18278116 | 0.93 | MAPK10 (0.42) | MAPK10MAPK8MAPK9STAT6MAPT | |
| SCHEMBL18278141 | 0.92 | MAPK8 (0.37) | MAPK10MAPK8MAPK9CCNT1CCNA2 | |
| SCHEMBL18278483 | 0.92 | MAPK10 (0.41) | MAPK10MAPK8MAPK9CCNT1CCNA2 | |
| SCHEMBL18277916 | 0.92 | MAPK8 (0.41) | MAPK10MAPK8MAPK9CCNT1CCNA2 | |
| SCHEMBL18278679 | 0.91 | MAPK8 (0.33) | MAPK10MAPK8MAPK9ACVR1MAPK14 | |
| SCHEMBL18278074 | 0.91 | MAPK8 (0.34) | MAPK10MAPK8MAPK9CCNT1CCNA2 | |
| SCHEMBL18294381 | 0.91 | MAPK8 (0.37) | MAPK10MAPK8MAPK9FGFR1KDR | |
| SCHEMBL18278369 | 0.91 | MAPK8 (0.38) | MAPK10MAPK8MAPK9CCNT1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | claimed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | claimed |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | claimed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | VERTEX PHARMACEUTCALS INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMA (US) | 2019-06-20 | — | — | US | disclosed |
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3302465-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197009-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118904-B2 | Triazoles for the treatment of Demyelinating Diseases | PMP22, MYT1, IKZF3 | MAPK10 4557/4885MAPK8 4491/4885MAPK9 3736/4885 |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | MAPK10 4557/4885MAPK8 4491/4885MAPK9 3736/4885 |
| US-10766869-B2 | Triazoles for the treatment of demyelinating dieases | PMP22, MYT1, IDE | MAPK10 4659/4885MAPK8 4224/4885MAPK9 3303/4885 |
| US-20190185436-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | PMP22, MYT1, IKZF3 | MAPK10 4557/4885MAPK8 4491/4885MAPK9 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.